Recurring Mistakes (And Remedies) For Life Sciences M&A
Life science management teams fall victim to recurring mistakes and entrapments. This article discusses avoidable missteps in M&A transactions and their respective remedies.
Recurring Mistakes (And Remedies) For Life Sciences M&A
Published in Life Science Leader, January 2018
Authors: Dr. Oded Ben-Joseph and Thomas Busby
As members of a specialized life sciences investment banking group focused on private equity financing and M&A, we often note that life science management teams fall victim to recurring mistakes and entrapments. Below is a list of avoidable missteps in M&A transactions and their respective remedies.
Events
Cambridge in America — University of Cambridge Alumni in Life Sciences
Tuesday, July 23 6:00-7:30pm Cost: This event is hosted by Dr. Oded Ben-Joseph (Darwin 1988), Managing Director, Outcome Capital, LLC, and is free to attend with prior RSVP. Outcome Capital, LLC 99 High Street, Suite 2900 Boston, MA RSVP to Megan Cokely at megan@cantab.org Cambridge in America’s Boston Regional Committee invites you to another exclusive event for […]
Read MoreNews
Outcome Capital Secures Growth Capital for Whisker Labs
Outcome Capital Secures Growth Capital for Whisker Labs November 26, 2019, Reston, VA Outcome Capital, an investment banking firm that serves middle market growth companies in the technology and life sciences space, is pleased to announce that Whisker Labs, Inc. (the “Company”) has secured growth capital from State Farm Ventures and Ferguson Ventures along with […]
Read MoreContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2020. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy
